March 10th 2025
Stark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Revolutionizing Atopic Dermatitis (RAD) Conference 2025
June 6-7, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Higher Psoriatic Arthritis Disease Burden Found Among Hispanic, Non-White Patients
February 18th 2025Hispanic and non-White patients with psoriatic arthritis (PsA) had higher tender joint counts and greater disease severity, highlighting racial and ethnic disparities in PsA disease burden and treatment outcomes.
Fighting the Flare of GPP: Expert Insights on Spesolimab
December 18th 2024Experts discussed the challenges of managing GPP and highlight a pivotal study on the subcutaneous formulation of spesolimab, demonstrating its potential to prevent GPP flares and improve patient outcomes despite some limitations.